|1.||Parle, Milind: 4 articles (01/2011 - 07/2003)|
|2.||Novío, Silvia: 3 articles (09/2012 - 12/2010)|
|3.||Freire-Garabal, Manuel: 3 articles (09/2012 - 12/2010)|
|4.||Greenblatt, D J: 3 articles (12/2000 - 01/2000)|
|5.||Davis, Stephen N: 2 articles (09/2015 - 04/2010)|
|6.||Hedrington, Maka S: 2 articles (09/2015 - 04/2010)|
|7.||Tate, Donna B: 2 articles (09/2015 - 04/2010)|
|8.||Stein, Dan J: 2 articles (01/2015 - 10/2011)|
|9.||Khanam, Razia: 2 articles (02/2014 - 06/2012)|
|10.||Berardelli, Rita: 2 articles (09/2013 - 01/2006)|
|1.||Panic Disorder (Panic Attack)
08/01/1993 - "These results suggest that sustained-release alprazolam is highly effective in the acute treatment of panic disorder at doses comparable to those in the originally marketed compressed tablet of alprazolam. "
12/01/1984 - "Blockade of panic attacks with TCAs, MAOIs and alprazolam has dramatically improved our ability to treat these disorders, with 60 to 95 per cent of patients reporting marked alleviation of symptoms. "
06/01/1986 - "Alprazolam treatment led to a complete remission of panic attacks in 85% of the patients; panics ceased within an average of 6 days, at a mean dose of 2.2 mg/day. "
10/01/1993 - "Studies of plasma alprazolam concentration versus clinical response during short-term treatment of panic disorder indicate that therapeutic response at steady-state plasma levels of 20 to 40 ng/mL is significantly greater than at levels less than 20 ng/mL. Substantial additional benefit from plasma levels greater than 40 ng/mL is not consistently demonstrated. "
04/01/1992 - "A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam. "
01/01/1999 - "A previous study with agoraphobia/panic patients found that the BZ alprazolam impaired memory during an 8-week treatment and residual impairments were still manifest several weeks after drug withdrawal (Curran et al. 1994). "
01/01/1999 - "Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients."
10/01/1991 - "House calls and alprazolam for agoraphobia."
01/01/1988 - "Fading of therapeutic effects of alprazolam in agoraphobia. "
01/01/1987 - "A double blind study of alprazolam and placebo in 118 patients with agoraphobia and panic is presented. "
|3.||Anxiety Disorders (Anxiety Disorder)
09/30/2015 - "This study investigated the temporal pattern of brain response to emotional stimuli during 28 days of alprazolam treatment among patients with generalized anxiety disorder (GAD) randomized 2:1 to drug or placebo in a double-blind design. "
01/01/2015 - "Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): observational study protocol."
10/01/2009 - "The scale was administered during the screening visit of a 4-week, placebo-controlled study of alprazolam and an investigational compound in 211 patients with generalized anxiety disorder (GAD). "
06/01/2000 - "In study 2, 11 patients with anxiety disorders receiving alprazolam (0.8-2.4 mg/day) ingested grapefruit juice (600 ml/day) for 7 days. "
01/01/1998 - "Fifty-four patients with an anxiety disorder, stabilized on alprazolam, entered the study. "
|4.||Major Depressive Disorder (Major Depressive Disorders)
04/01/1988 - "Alprazolam appears to be an effective antidepressant in the treatment of outpatients who have a diagnosis of major depressive disorder. "
01/01/1989 - "Double-blind comparison of 3- and 6-mg fixed doses of alprazolam vs. placebo in outpatients with major depressive disorder."
11/01/1985 - "A woman with major depressive disorder and refractory, incapacitating migraine headaches responded to alprazolam in a double-blind, placebo-controlled study. "
04/01/1991 - "This report describes the results of a multicentre collaborative study comparing the safety and efficacy of alprazolam with imipramine in patients suffering from major depressive disorder. "
01/01/1990 - "Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study."
|5.||Depressive Disorder (Melancholia)
09/01/1981 - "Although alprazolam may be effective in patients with exogenous depression, no extrapolation can be made to the treatment of endogenous depression. "
01/01/1985 - "The clinical efficacy of alprazolam has been evaluated in both anxiety states and depressive disorders. "
02/01/1991 - "The pharmacokinetics of alprazolam was studied in 10 geriatric patients (5 males, 5 females) with neurotic depression during a 6-week period. "
02/01/1991 - "Pharmacokinetics of alprazolam in geriatric patients with neurotic depression."
12/01/1989 - "Double blind comparison of alprazolam with dosulepine in endogenous depression."
|8.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
|10.||Tricyclic Antidepressive Agents (Tricyclic Antidepressants)
|1.||Drug Therapy (Chemotherapy)
|2.||Estrogen Replacement Therapy